(Q44572216)

4 December 2017

title

Early development of anti-natalizumab antibodies in MS patients (English)

1 reference

4 December 2017

B Oliver-Martos

1

1 reference

4 December 2017

T Órpez-Zafra

2

1 reference

4 December 2017

P Urbaneja

3

1 reference

4 December 2017

R Maldonado-Sanchez

4

1 reference

4 December 2017

L Leyva

5

1 reference

4 December 2017

O Fernández

6

1 reference

4 December 2017

publication date

14 June 2013

1 reference

4 December 2017

1 reference

4 December 2017

volume

260

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

2343-2347

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-013-6991-2

4 December 2017

exact match

0 references

cites work

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6991-2

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6991-2

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6991-2

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6991-2

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6991-2

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23765090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23765090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23765090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-013-6991-2

1 reference

4 December 2017

1 reference